LSD-Quinoline
LSD-Quinoline is a serotonin receptor modulator related to the lysergamide family and to lysergic acid diethylamide (LSD), first synthesised by David E.
≈ 2 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
LSD-Quinoline is a serotonin receptor modulator related to the lysergamide family and to lysergic acid diethylamide (LSD), first synthesised by David E. Olson and colleagues. It acts as a moderately selective serotonin receptor agonist, primarily at the serotonin 5-HT 2A receptor, though its activity at other subtypes such as the 5-HT 2B and 5-HT 2C receptors, and at other targets of LSD such as dopamine receptors, has not been published.
It was developed in the course of resarch into non-hallucinogenic psychoplastogens, and is described as having around 24x lower potency than LSD and with "reduced hallucinogenic potential", though this would suggest it may still be of a similar potency to many psychedelic tryptamine derivatives. It has been researched for therapeutic applications including as a potential antidepressant.
LSD-Quinoline was first described in the scientific literature by 2026.
See also
Substituted lysergamide § Related compounds JRT (drug) Mefloquine
Text derived from https://en.wikipedia.org/w/index.php?oldid=1374730835 under CC BY-SA 4.0; modifications have been made.